ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Pfizer invests $500 million in gene-therapy manufacturing

by Ryan Cross
August 24, 2019 | APPEARED IN VOLUME 97, ISSUE 33

 

Upping its commitment to gene therapy, Pfizer says it will invest $500 million in its manufacturing facility in Sanford, North Carolina. The time and cost of making the quadrillions of viruses used to deliver DNA have been major holdups for the entire gene-therapy field. Manufacturing is particularly important for Pfizer, which is focused on treating relatively common conditions like hemophilia B and muscular dystrophy. Commercialization of such therapies will require an unprecedented production scale-up. Pfizer has 650 employees in Sanford and is adding about 300 more.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment